Emergent Biosolutions Company Insiders
| EBS Stock | USD 2.16 0.12 5.88% |
Emergent Biosolutions' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Emergent Biosolutions suggests that vertually all insiders are panicking. Emergent Biosolutions employs about 1.6 K people. The company is managed by 32 executives with a total tenure of roughly 119 years, averaging almost 3.0 years of service per executive, having 50.0 employees per reported executive.
| Daniel AbdunNabi CEO President CEO, Director |
| Fuad ElHibri Chairman Executive Chairman of the Board |
Emergent Biosolutions' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2023-06-02 | Kathryn C Zoon | Disposed 1830 @ 8.35 | View | ||
| 2023-05-25 | Kathryn C Zoon | Disposed 1700 @ 8.38 | View |
Monitoring Emergent Biosolutions' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Emergent |
Emergent Biosolutions' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Emergent Biosolutions' future performance. Based on our forecasts, it is anticipated that Emergent will maintain a workforce of slightly above 1600 employees by May 2024.Emergent Biosolutions' latest congressional trading
Congressional trading in companies like Emergent Biosolutions, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Emergent Biosolutions by those in governmental positions are based on the same information available to the general public.
| 2021-11-05 | Representative Josh Gottheimer | Disposed Under $15K | Verify | ||
| 2020-11-24 | Representative Gilbert Cisneros | Acquired Under $15K | Verify | ||
| 2020-03-26 | Representative Steve Cohen | Disposed Under $15K | Verify |
Emergent Biosolutions Management Team Effectiveness
The company has Return on Asset of (0.048) % which means that on every $100 spent on assets, it lost $0.048. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.7467) %, meaning that it generated no profit with money invested by stockholders. Emergent Biosolutions' management efficiency ratios could be used to measure how well Emergent Biosolutions manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.57 in 2024. Return On Capital Employed is likely to gain to -0.14 in 2024. At this time, Emergent Biosolutions' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 2.4 B in 2024, whereas Deferred Long Term Asset Charges is likely to drop slightly above 9 M in 2024.Common Stock Shares Outstanding is likely to drop to about 41.4 M in 2024. Net Loss is likely to gain to about (244.5 M) in 2024
Emergent Biosolutions Workforce Comparison
Emergent Biosolutions is rated # 5 in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 43,867. Emergent Biosolutions holds roughly 1,600 in number of employees claiming about 4% of equities under Health Care industry.
The company has Net Profit Margin of (0.72) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.18) %, which entails that for every $100 of revenue, it lost $0.18. Emergent Biosolutions Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Emergent Biosolutions insiders, such as employees or executives, is commonly permitted as long as it does not rely on Emergent Biosolutions' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Emergent Biosolutions insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 0.4615 | 6 | 13 | 1,375,000 | 20,704 |
| 2023-12-01 | 0.4 | 2 | 5 | 237,340 | 1,611 |
| 2023-06-01 | 9.0 | 27 | 3 | 1,094,340 | 3,530 |
| 2023-03-01 | 0.8519 | 23 | 27 | 214,095 | 37,219 |
| 2022-12-01 | 2.0 | 4 | 2 | 152,490 | 2,328 |
| 2022-09-01 | 1.0 | 1 | 1 | 11,852 | 0.00 |
| 2022-06-01 | 3.0 | 9 | 3 | 73,630 | 3,169 |
| 2022-03-01 | 0.92 | 23 | 25 | 614,578 | 35,653 |
| 2021-06-01 | 1.3333 | 8 | 6 | 45,494 | 18,015 |
| 2021-03-01 | 0.9474 | 36 | 38 | 392,293 | 255,549 |
| 2020-12-01 | 0.4444 | 4 | 9 | 63,020 | 158,782 |
| 2020-09-01 | 0.1333 | 2 | 15 | 15,786 | 169,831 |
| 2020-06-01 | 0.3421 | 13 | 38 | 78,925 | 410,308 |
| 2020-03-01 | 0.7 | 35 | 50 | 465,784 | 357,407 |
| 2019-12-01 | 0.5 | 2 | 4 | 10,306 | 17,610 |
| 2019-06-01 | 1.3333 | 8 | 6 | 48,045 | 12,495 |
| 2019-03-01 | 0.7778 | 21 | 27 | 270,740 | 97,868 |
| 2018-12-01 | 0.5 | 17 | 34 | 139,457 | 290,255 |
| 2018-09-01 | 0.5 | 7 | 14 | 126,971 | 235,485 |
| 2018-06-01 | 1.6667 | 15 | 9 | 77,534 | 54,278 |
| 2018-03-01 | 0.8846 | 23 | 26 | 326,251 | 139,499 |
| 2017-12-01 | 0.375 | 9 | 24 | 157,423 | 400,642 |
| 2017-09-01 | 0.375 | 9 | 24 | 107,501 | 303,565 |
| 2017-06-01 | 7.0 | 7 | 1 | 57,813 | 11,419 |
| 2017-03-01 | 0.7931 | 23 | 29 | 422,910 | 160,301 |
| 2016-12-01 | 0.5 | 1 | 2 | 14,226 | 5,900 |
| 2016-06-01 | 0.9661 | 57 | 59 | 489,866 | 581,152 |
| 2016-03-01 | 0.7429 | 26 | 35 | 414,787 | 215,429 |
| 2015-12-01 | 0.4615 | 12 | 26 | 226,411 | 408,048 |
| 2015-09-01 | 0.2727 | 3 | 11 | 13,280 | 96,404 |
| 2015-06-01 | 0.7241 | 21 | 29 | 175,643 | 291,903 |
| 2015-03-01 | 0.7647 | 13 | 17 | 414,390 | 88,145 |
| 2014-12-01 | 0.2273 | 5 | 22 | 29,576 | 206,005 |
| 2014-06-01 | 8.0 | 16 | 2 | 99,496 | 50,189 |
| 2014-03-01 | 0.8667 | 13 | 15 | 539,340 | 70,236 |
| 2013-12-01 | 2.0 | 4 | 2 | 50,788 | 5,832 |
| 2013-09-01 | 2.0 | 2 | 1 | 16,200 | 0.00 |
| 2013-06-01 | 7.5 | 15 | 2 | 471,337 | 114,872 |
| 2013-03-01 | 0.7333 | 11 | 15 | 289,566 | 33,895 |
| 2012-12-01 | 1.0 | 7 | 7 | 733,664 | 288,645 |
| 2012-09-01 | 0.5 | 2 | 4 | 170,000 | 333,870 |
| 2012-06-01 | 1.0833 | 13 | 12 | 345,990 | 2,285,088 |
| 2012-03-01 | 1.0 | 10 | 10 | 206,400 | 17,517 |
| 2011-09-01 | 2.0 | 2 | 1 | 210,952 | 500,000 |
| 2011-06-01 | 1.08 | 27 | 25 | 586,623 | 420,146 |
| 2011-03-01 | 1.2 | 12 | 10 | 274,991 | 60,794 |
| 2010-12-01 | 0.6667 | 6 | 9 | 65,289 | 106,578 |
| 2010-09-01 | 0.3846 | 5 | 13 | 260,487 | 790,092 |
| 2010-06-01 | 1.5 | 21 | 14 | 452,266 | 858,600 |
| 2010-03-01 | 5.5 | 11 | 2 | 288,428 | 40,000 |
| 2009-09-01 | 0.2821 | 11 | 39 | 421,952 | 1,201,274 |
| 2009-06-01 | 8.0 | 8 | 1 | 577,330 | 700,000 |
| 2009-03-01 | 4.0 | 4 | 1 | 161,400 | 7,200 |
| 2008-12-01 | 0.0435 | 3 | 69 | 41,490 | 285,180 |
| 2008-09-01 | 0.0035 | 1 | 286 | 17,500 | 407,800 |
| 2008-06-01 | 0.1 | 6 | 60 | 117,960 | 1,157,168 |
| 2008-03-01 | 0.0455 | 2 | 44 | 140,000 | 251,584 |
| 2007-06-01 | 0.4341 | 56 | 129 | 678,713 | 1,031,669 |
| 2006-12-01 | 0.8 | 20 | 25 | 1,914,149 | 2,208,232 |
Emergent Biosolutions Notable Stakeholders
An Emergent Biosolutions stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Emergent Biosolutions often face trade-offs trying to please all of them. Emergent Biosolutions' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Emergent Biosolutions' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Daniel AbdunNabi | President CEO, Director | Profile | |
| Joseph Papa | CEO President | Profile | |
| Fuad ElHibri | Executive Chairman of the Board | Profile | |
| Zsolt Harsanyi | Non-Executive Independent Chairman of the Board | Profile | |
| Sean Kirk | Executive Vice President - Manufacturing and Technical Operations | Profile | |
| Robert Kramer | CFO, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer | Profile | |
| Katherine Strei | Executive Vice President - Human Resources and Communications, Chief Human Resources Officer | Profile | |
| Atul Saran | Executive Vice President Corporate Development, General Counsel and Corporate Secretary | Profile | |
| Adam Havey | Executive VP and President of Biodefense Division | Profile | |
| Richard Lindahl | Chief Financial Officer, Executive Vice President, Treasurer | Profile | |
| Richard MBA | CFO VP | Profile | |
| Sue Bailey | Independent Director | Profile | |
| Jerome Hauer | Independent Director | Profile | |
| Kathryn Zoon | Independent Director | Profile | |
| Seamus Mulligan | Director | Profile | |
| George Joulwan | Independent Director | Profile | |
| Louis Sullivan | Independent Director | Profile | |
| Ronald Richard | Lead Independent Director | Profile | |
| Stephanie Duatschek | Chief VP | Profile | |
| Kelly Warfield | Senior Development | Profile | |
| William Hartzel | Senior Bioservices | Profile | |
| Robert Burrows | IR Contact Officer | Profile | |
| Haywood Miller | Interim Officer | Profile | |
| Karen Smith | Executive Vice President Chief Medical Officer | Profile | |
| Paul Williams | Senior Business | Profile | |
| Keith Katkin | Independent Director | Profile | |
| Jennifer Fox | Executive Vice President - External Affairs, General Counsel, Corporate Secretary | Profile | |
| Michelle Pepin | Senior Officer | Profile | |
| Coleen Glessner | Executive Compliance | Profile | |
| Lynn Kieffer | VP Communications | Profile | |
| Marvin White | Director | Profile | |
| Robert Sr | Pres CEO | Profile |
About Emergent Biosolutions Management Performance
The success or failure of an entity such as Emergent Biosolutions often depends on how effective the management is. Emergent Biosolutions management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Emergent management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Emergent management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.60) | (0.57) | |
| Return On Capital Employed | (0.15) | (0.14) | |
| Return On Assets | (0.41) | (0.39) | |
| Return On Equity | (1.17) | (1.11) |
The data published in Emergent Biosolutions' official financial statements usually reflect Emergent Biosolutions' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Emergent Biosolutions. For example, before you start analyzing numbers published by Emergent accountants, it's critical to develop an understanding of what Emergent Biosolutions' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Emergent Biosolutions' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Emergent Biosolutions' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Emergent Biosolutions' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Emergent Biosolutions. Please utilize our Beneish M Score to check the likelihood of Emergent Biosolutions' management manipulating its earnings.
Emergent Biosolutions Workforce Analysis
Traditionally, organizations such as Emergent Biosolutions use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Emergent Biosolutions within its industry.Emergent Biosolutions Manpower Efficiency
Return on Emergent Biosolutions Manpower
| Revenue Per Employee | 700.6K | |
| Revenue Per Executive | 35M | |
| Net Loss Per Employee | 139.9K | |
| Net Loss Per Executive | 7M | |
| Working Capital Per Employee | 17.6K | |
| Working Capital Per Executive | 881.2K |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Emergent Biosolutions. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy Emergent Stock please use our How to Invest in Emergent Biosolutions guide.Note that the Emergent Biosolutions information on this page should be used as a complementary analysis to other Emergent Biosolutions' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Emergent Stock analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is Emergent Biosolutions' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Emergent Biosolutions. If investors know Emergent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Emergent Biosolutions listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.022 | Earnings Share (14.85) | Revenue Per Share 20.494 | Quarterly Revenue Growth (0.16) | Return On Assets (0.05) |
The market value of Emergent Biosolutions is measured differently than its book value, which is the value of Emergent that is recorded on the company's balance sheet. Investors also form their own opinion of Emergent Biosolutions' value that differs from its market value or its book value, called intrinsic value, which is Emergent Biosolutions' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Emergent Biosolutions' market value can be influenced by many factors that don't directly affect Emergent Biosolutions' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Emergent Biosolutions' value and its price as these two are different measures arrived at by different means. Investors typically determine if Emergent Biosolutions is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Emergent Biosolutions' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.